Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I/IIa AdCD40L immunogene therapy for malignant melanoma in patients with disseminated disease

Proposed period of release:
01/05/2011 to 31/05/2013

Name of the Institute(s) or Company(ies)
Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden.;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
AdCD40L is consisting of a recombinant adenovirus group C serotype 5 E1E3 deleted vector expressing the human CD40L (CD154) gene under controll of a promoter derived from Rous Sarcoma Virus (RSV) (Leimig et al Human Gene Ther 7:1233-1239, 1996; Takahashi et al Hum Gene Ther 12:659-670, 2001).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Adenovirus human serotype 5 (Ad5)Mastadenovirushuman adenovirussubgroup Cserotype 5

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known